2025 Egyptian guidelines for the management of dyslipidemia
Authors:
- Ashraf RedaARAshraf Reda
- Hesham S. TahaHTHesham S. Taha
- Hala Mahfouz BadranHBHala Mahfouz Badran
- Hazem KhamisHKHazem Khamis
- Sherif KamalSKSherif Kamal
- Ahmed Shawky ElserafyAEAhmed Shawky Elserafy
- Ahmed Adel ElamragyAEAhmed Adel Elamragy
- Ahmed BendaryABAhmed Bendary
- Mirna Mamdouh ShakerMSMirna Mamdouh Shaker
Open Access
- 20 January 2026
- journal article
- review article
- Published by Springer Nature in The Egyptian Heart Journal
- Vol. 78 (1) , 6
Abstract
Background: The burden of premature atherosclerotic cardiovascular disease (ASCVD) in Egypt remains disproportionately high, and current international dyslipidemia guidelines have proven insufficient in achieving target lipid levels in the local population. This underscores the necessity for a context-specific national guideline. The 2025 Egyptian Guidelines for the Management of Dyslipidemia were developed through a structured consensus process led by an expert panel of cardiologists, endocrinologists, and representatives from national medical societies. Main text: The methodology included two rounds of blind voting followed by a consensus meeting to ensure rigorous evaluation. The guidelines emphasize the importance of early detection of dyslipidemia through systematic screening programs and prioritize lifestyle interventions as the cornerstone of management. A novel “extreme-risk” category was introduced to identify patients requiring intensified lipid-lowering strategies, including early initiation of combination pharmacotherapy. Additionally, the recommendations highlight the critical role of ongoing monitoring and follow-up to sustain long-term lipid control and reduce cardiovascular risk. Conclusion: The current guidelines provide a simplified, yet evidence-based framework tailored to the Egyptian population, aiming to optimize dyslipidemia management, reduce ASCVD-related complications, and improve overall cardiovascular outcomes.Keywords
This publication has 88 references indexed in Scilit:
- Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin TherapyJACC, 2010
- Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trialsJournal of Internal Medicine, 2009
- Contraceptive Hormone Use and Cardiovascular DiseaseJACC, 2009
- Fasting and Nonfasting Lipid LevelsCirculation, 2008
- Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.The American Journal of Cardiology, 2008
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005
- Bezafibrate in men with lower extremity arterial disease: randomised controlled trialBMJ, 2002
- Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet actionJournal of Vascular Surgery, 2002
- Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 FamiliesArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987